US Hospital studies a Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty
Photo by Fabrizio Verrecchia
The Massachusetts Eye and Ear Infirmary is conducting the clinical trial Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty.
This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts.
Actual study start date is January 1, 2021. The researchers expect to complete the study by January 2022.
One primary outcome measure is Change in central corneal pachymetry over time, Corneal thickness on clinical examination and corneal topography.
Patients with Fuchs corneal dystrophy can be enrolled into this study.
The exclusion parameters are:
- Other corneal eye diseases
- Non-compliance with netarsudil
- Intolerance of netarsudil
The Sponsor and recruiting facility is Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States, 02127.
Massachusetts Eye and Ear (Mass. Eye and Ear, or MEE) is a specialty hospital located in Boston, Massachusetts, United States, which focuses on ophthalmology (eye), otolaryngology (ear/nose/throat), and related medicine and research. Founded in 1824 as the Boston Eye Infirmary (BEI), it has also been known as the Massachusetts Charitable Eye and Ear Infirmary (MCEEI), and Massachusetts Eye and Ear Infirmary (MEEI). It is a teaching partner of Harvard Medical School.
The following link provides further details and information: https://ichgcp.net/clinical-trials-registry/NCT04752020
